Dry Eye Clinical Trial - Topical Cyclosporine A for the Treatment of Dry

Status Completed

Clinical Trial Summary

Since the initial description, the therapeutic efficacy of CsA for human KCS has been well documented, with evidence ranging from several small single center randomized double-masked clinical trials to several large multicenter randomized, double-masked clinical trials.(10-12) Therefore, the aim of the work is to evaluate the effect of using topical CsA in treatment of moderate to severe dry eye.

Clinical Trial Description

Dry eye disease (DED) is known to be among the most frequently occuring ocular morbidities. It is a growing public health concern affecting 25% of patients who visit ophthalmic clinics.For many years, DED was considered to be limited to dryness of the eyes due to decrease in the aqueous phase in the tear film. In 2007, the International Dry Eye Workshop discussed the definition and classification of DED and developed a new vision for the definition and the three-part classification of DED on the basis of etiology, mechanism, and severity of DED. Moreover, DED can be episodic or chronic. Episodic DED occurs when environmental or visual tasks with reduced blinking overwhelm the stability of the tear and produce symptomatic DED. Chronic DED, although aggravated by the same environmental conditions, persists continuously with symptoms and possible damage to the ocular surface. Because the tear film in DED patients is not stable and incapable to maintain the protective qualities that are important for its structure and function, patients usually experience the discomfort manifestations associated with DED such as burning, stinging, foreign body sensation, ocular fatigue, grittiness, tearing, and dryness. Patients may complain of symptoms of DED in the presence or absence of the known signs and DED may be diagnosed based only on the signs observed by a healthcare professional in the absence of symptoms reported by the patients.Since the initial description, the therapeutic efficacy of CsA for human KCS has been well documented, with evidence ranging from several small single center randomized double-masked clinical trials to several large multicenter randomized, double-masked clinical trials.Therefore, the aim of the work is to evaluate the effect of using topical CsA in treatment of moderate to severe dry eye. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04714099
Study type	Interventional
Source	Alexandria University
Contact
Status	Completed
Phase	Phase 3
Start date	January 1, 2015
Completion date	December 30, 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT06159569` - Performance and Tolerability of the Medical Device LACRIACT	N/A
Completed	`NCT05027087` - The Effect of a Novel Blueberry Supplement on Dry Eye Disease	Phase 3
Completed	`NCT05102409` - An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease	Phase 2
Completed	`NCT04081610` - Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution	Phase 1
Completed	`NCT05062564` - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye	N/A
Completed	`NCT05825599` - PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms	N/A
Completed	`NCT03418727` - Dry Eye Disease Study With Brimonidine	Phase 2
Active, not recruiting	`NCT04425551` - Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction	N/A
Recruiting	`NCT04527887` - Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED)	Phase 4
Not yet recruiting	`NCT06379685` - Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.	Phase 1
Active, not recruiting	`NCT05618730` - Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B	Phase 1
Completed	`NCT04553432` - Dry Eye OmniLenz Application of Omnigen Research Study	Phase 4
Recruiting	`NCT04109170` - Dry Eye Evaluation System Based on Bioinformatics
Completed	`NCT04105842` - Refitting Daily Disposable Contact Lens Wearers With Dry Eye Disease With A Different Daily Disposable Lens Type	N/A
Completed	`NCT05505292` - Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers	Phase 4
Completed	`NCT04668131` - Study on Curative Effect and Mechanism of Acupuncture on Neuropathic Pain in Dry Eye Disease	N/A
Completed	`NCT06176651` - Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers	Phase 4
Not yet recruiting	`NCT02218827` - Topical Steroid Treatment For Dry Eye	N/A
Completed	`NCT02235259` - Efficacy and Safety of XG-104 for the Treatment of Dry Eye	Phase 2
Completed	`NCT01959854` - Efficacy of Topical 0.2% Xanthan Gum in Patients With Dry Eye	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Topical Cyclosporine A for the Treatment of Dry Eye: A Randomized Clinical Study

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms